Research scope: This page is for qualified laboratory and in-vitro research only. It contains no dosing, administration, medical, human-use, or veterinary-use guidance.
What the name usually describes
A supplier-specific blend combining Cartalax with BPC-157 and a TB-500-labeled material.
Also marketed as: Wolverine+.
Formula and component amounts can differ by supplier and over time. The product label, finished-lot report, and exact molecular identities control—not the blend nickname.
Evidence boundary
The marketing name and formula are not standardized across the market. Evidence for this exact mixture has not been established in peer-reviewed research.
A study of one constituent does not demonstrate synergy, stability, safety, or any claimed outcome for a co-lyophilized mixture.
Finished-blend documentation checks
- Require the identity and stated mass of every component—not only a total vial mass or a single HPLC area result.
- Confirm whether testing was performed on the finished co-formulated blend or inferred from separate ingredient records.
- Record the exact formula, component ratio, lot number, report date, methods, and supplier because the marketing name alone is not a chemical specification.
Research starting points
Review the individual component pages before evaluating a blend:
Cartalax
BPC-157
TB-500 / thymosin-beta-4-related material